ALNA News and Press, Allena Pharmaceuticals Inc. From 11/03/21

- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract - - Patients with gout and CKD have a serious condition with an unmet need for urate-lowering–therapies – -Two Phase 2a studies currently enrolling patients with hyperuricem...

- Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease - - Novel therapeutic candidate targets uric acid in the GI tract - - Initial data expected in late 2021 or early 2022 - NEWTON, Mass., Sept. 29, 2021 (GLOBE NEWSW...

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabo...

ALLN-346 well-tolerated in recently completed Phase 1b study; first patients dosed in Phase 2a program for gout and chronic kidney disease; initial data expected in Q4 2021 June KOL webinar highlighted the unmet need in gout and potential for ALLN-346 Updated plan and ...

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...

Shares of Allena Pharmaceuticals Inc. (NASDAQ:ALNA) traded today at $0.77, breaking its 52-week low. So far today approximately 5.8 million shares have been exchanged, as compared to an average 30-day volume of 2.4 million shares. Allena Pharmaceuticals Inc is a late-stage clinical bioph...

Shares of Allena Pharmaceuticals Inc. (NASDAQ:ALNA) traded at a new 52-week low today of $0.96. So far today approximately 3 million shares have been exchanged, as compared to an average 30-day volume of 491,000 shares. In the past 52 weeks, Allena Pharmaceuticals Inc. share prices are b...

Gainers: AcelRx Pharmaceuticals ACRX +19%, GBS (GBS) +13%, Navidea Biopharmaceuticals (NAVB) +7%, Cellect Biotechnology (APOP) +6%, Adagene (ADAG) +2%.Losers: Allied Healthcare Products (AHPI) -34%, Allena Pharmaceuticals (ALNA) -31%, SCWorx (WORX)...

Allied Healthcare Products (AHPI) -24%.Glaukos (GKOS) -21% comments on the centers for medicare and medicaid services 2022 proposed physician fee scheduleAllena Pharmaceuticals (ALNA) -20% after launches $28M direct offeringIMARA (IMRA) -15% after secures $50M capital...

Allena Pharmaceuticals (ALNA) inks agreements with several institutional and accredited investors for the purchase and sale of 21,357,744 common shares and warrants to purchase up to 10,678,872 common stock, at $1.311/share and warrant, in a registered direct offering priced at-the-market.Exp...